Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 1:13 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 1,054 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Sensitive Skin Clear all

Conditions: Atopic Dermatitis
Interventions: Combination of pimecrolimus and fluticasone, pimecrolimus; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 2 Years to 65 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 3
States / cities: Denver, Colorado • Chicago, Illinois • Houston, Texas

Conditions: Dry Eyes, Allergic Conjunctivitis
Interventions: Not listed
Lead sponsor: Schwartz Laser Eye Center; Other
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Eczema, Hand Eczema, Atopic Dermatitis
Interventions: CLn BodyWash, Cetaphil Daily Facial Cleanser; Other
Lead sponsor: Shari L Hand; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Gahanna, Ohio

Conditions: Atopic Dermatitis
Interventions: Pimecrolimus; Drug
Lead sponsor: Novartis; Industry
Eligibility: 2 Years to 16 Years
Enrollment: 240 participants
Timeline: 2004 – 2005
U.S. locations: 0
States / cities: Not listed

Conditions: Atopic Dermatitis
Interventions: Soquelitinib, Placebo; Drug
Lead sponsor: Corvus Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 16
States / cities: Birmingham, Alabama • Tucson, Arizona • North Little Rock, Arkansas + 12 more

Conditions: Hereditary Angioedema (HAE)
Interventions: Donidalorsen; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 2 Years to 11 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 8
States / cities: Santa Monica, California • Miami, Florida • Baton Rouge, Louisiana + 5 more

Conditions: Skin Inflammation, Allergic Contact Dermatitis
Interventions: Squaric Acid Dibutyl Ester, Known patch test allergens, Dupilumab, Adalimumab, Ustekinumab, Guselkumab, Canakinumab, Sarilumab, Triamcinolone Acetonide, Betamethasone Valerate, Fluticasone Propionate, Microneedle, Suction blistering, Skin punch biopsy; Drug · Other · Device + 1 more
Lead sponsor: Wei-Che Ko; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Atopic Dermatitis
Interventions: 5 mg ASB17061, Placebo, 10 mg ASB17061, 20 mg ASB17061; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 370 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 40
States / cities: Birmingham, Alabama • Phoenix, Arizona • Rogers, Arkansas + 35 more

Conditions: Atopic Dermatitis, Atopic Dermatitis Eczema, Eczema
Interventions: IMG-007; Drug
Lead sponsor: Inmagene LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 16
States / cities: Lancaster, California • Los Angeles, California • Ocala, Florida + 13 more

Conditions: Asthma, Eczema, Dermatitis, Atopic
Interventions: Not listed
Lead sponsor: Indiana University; Other
Eligibility: 2 Months to 7 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2012
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Pruritus, Atopic Dermatitis
Interventions: Serlopitant High Dose, Placebo Oral Tablet, Serlopitant Low Dose; Drug
Lead sponsor: Vyne Therapeutics Inc.; Industry
Eligibility: 13 Years and older
Enrollment: 484 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 52
States / cities: Anniston, Alabama • Birmingham, Alabama • Hoover, Alabama + 44 more

Conditions: Allergic Rhinitis, Allergic Conjunctivitis
Interventions: olopatadine, placebo; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Chronic Spontaneous Urticaria
Interventions: Ligelizumab; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 17
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 14 more

Conditions: Atopic Dermatitis
Interventions: DS107, Placebo; Drug
Lead sponsor: DS Biopharma; Industry
Eligibility: 18 Years and older
Enrollment: 219 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 26
States / cities: Birmingham, Alabama • Huntington Beach, California • Los Angeles, California + 22 more

Conditions: Allergy, Hypersensitivity, Immediate, Ig-E Mediated Food
Interventions: AllerTest-10 Multi-Head Skin Test Device, Skintestor OMNI Multi-Head Skin Test Device, Multi-Test II Multi-Head Skin Test Device, AllerTest-8 Multi-Head Skin Test Device; Device
Lead sponsor: QHSLab, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Atopic Dermatitis
Interventions: 0417, Vehicle of 0417 test product, Tacrolimus Ointment 0.03%; Drug
Lead sponsor: Fougera Pharmaceuticals Inc.; Industry
Eligibility: 8 Years and older
Enrollment: 899 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Melville, New York

Conditions: Chronic Spontaneous Urticaria (CSU), Chronic Idiopathic Urticaria
Interventions: THB335 Lower Dose, THB335 Higher Dose, Placebo; Drug
Lead sponsor: Calixis Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 15
States / cities: Pasadena, California • Ventura, California • Walnut Creek, California + 12 more

Conditions: Chronic Spontaneous Urticaria
Interventions: barzolvolimab, Matching Placebo; Biological · Drug
Lead sponsor: Celldex Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 13
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 10 more

Conditions: Pulmonary Fibrosis of Any Cause, Primary Supporters/Caretakers of Patients With Pulmonary Fibrosis
Interventions: Not listed
Lead sponsor: National Jewish Health; Other
Eligibility: 18 Years to 100 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Atopic Dermatitis
Interventions: Fluocinonide Cream 0.1%; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 12 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Allergic Reaction
Interventions: Test Article, Positive Control, Negative Control; Device · Other
Lead sponsor: Omeza, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: St. Petersburg, Florida

Conditions: Atopic Dermatitis
Interventions: Ruxolitinib Cream, Vehicle Cream; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 241 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 18
States / cities: Little Rock, Arkansas • Fountain Valley, California • Fremont, California + 15 more

Conditions: Ewing Sarcoma, PEComa, Epithelioid Sarcoma, Desmoid Tumor, Chordoma, Non Small Cell Lung Cancer, Urothelial Carcinoma, Melanoma, Renal Cell Carcinoma, Squamous Cell Carcinoma, Hepatocellular Carcinoma, Classical Hodgkin Lymphoma, Colorectal Cancer, MTOR Activating Mutation
Interventions: Nab-Rapamycin, Nivolumab; Drug · Biological
Lead sponsor: Sarcoma Oncology Research Center, LLC; Other
Eligibility: 12 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Hereditary Angioedema
Interventions: C1 esterase inhibitor [human] (C1INH-nf); Biological
Lead sponsor: Shire; Industry
Eligibility: 1 Year and older
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 30
States / cities: Scottsdale, Arizona • Bentonville, Arkansas • Los Angeles, California + 27 more

Search by objective public record fields.

Combination Therapy for Atopic Dermatitis

Evaluating Patients With Eye Allergies and Determining if There Are Also Dry Eyes

A Study to Assess CLn® BodyWash for Reducing Skin Fauna in Patients With Hand Eczema

Extension Study of Pimecrolimus Cream in Pediatric Patients With Atopic Dermatitis

Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe AD

Donidalorsen Treatment in Children With Hereditary Angioedema

Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of ASB17061 Capsules in Adult Subjects With Atopic Dermatitis

Long-term Safety and Efficacy Evaluation of IMG-007 in Participants With Moderate-to-Severe Atopic Dermatitis

Risk of Asthma in Infants With Atopic Dermatitis

Study of the Efficacy, Safety, and Tolerability of Serlopitant for Pruritus (Itch) in Atopic Dermatitis

Olopatadine Eye Drops and Allergy Skin Testing

A Safety Extension Study to Evaluate the Long-term Safety of QGE031 in Chronic Spontaneous Urticaria (CSU) Patients

Efficacy and Safety of Orally Administered DS107 in Adult Patients With Moderate to Severe Atopic Dermatitis

Head-to-Head Comparison Study Between Different FDA Registered Allergy Skin Test Applicators

Study of 0417 Ointment in the Treatment of Atopic Dermatitis

A Study to Assess the Efficacy and Safety of THB335 in Adults With Chronic Spontaneous Urticaria (CSU)

A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria

Pulmonary Fibrosis Contact Registry

A Study Evaluating the Efficacy of Fluocinonide Cream 0.1% (Vanos) in Subjects With Atopic Dermatitis

Allergy Potential of Omeza Collagen Matrix in Human Subjects Using the Skin Prick Method

A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis

Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers

Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks